INTRODUCTION
In 2007, an estimated 59,940 new cases of melanoma were diagnosed and approximately 8,110 patients died of the disease in the United States. 1 Worldwide, the incidence of melanoma continues to rise at a rate of approximately 3% per year.
2 If detected and treated at an early stage, melanoma has a cure rate of approximately 90%. 3 In contrast, the prognosis for advanced disease is poor with an average 5-year survival rate of 18% and a median survival of 7.8 months.
4-6 Given these statistics, there is an urgent need to identify more effective therapeutic agents for the treatment of advanced melanoma.
While there is no widely accepted standard of care for metastatic melanoma, dacarbazine is the most commonly used cytotoxic agent. Dacarbazine has a moderate toxicity profile, but has a low objective response rate of 5% to 20% with a median progression-free survival (PFS) of 1.5 to 1.6 months and no improvement in overall survival (OS). [7] [8] [9] [10] Several investigators have attempted to combine targeted therapy and dacarbazine chemotherapy in an attempt to improve treatment response. Immunotherapy regimens, specifically those containing interferon-alfa and interleukin-2, and biochemotherapy have also been studied extensively in melanoma. [11] [12] [13] [14] [15] [16] [17] [18] To date, no current therapy, singleagent or combination, has resulted in improved survival compared with dacarbazine. 6, 7, 19 
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The Ras-Raf-MEK-ERK signaling pathway is activated in the vast majority of melanomas. Melanomas have been reported to be dependent on the activation of this pathway for replication and survival. [20] [21] [22] [23] Sorafenib is an inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent antitumor activity in human tumor xenografts. 24, 25 While sorafenib has limited single-agent activity in advanced melanoma, the combination of sorafenib and dacarbazine resulted in manageable toxicity and encouraging antitumor activity in phase I and open-label phase II studies. [26] [27] [28] [29] To further evaluate the safety and efficacy of adding sorafenib to dacarbazine in patients with advanced melanoma, we conducted a randomized phase II, doubleblind, placebo-controlled trial.
PATIENTS AND METHODS

Patients
Eligible patients were at least 18 years old, had histologically or cytologically confirmed unresectable stage III or stage IV melanoma, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable disease defined by at least one lesion that could be accurately and serially measured per modified Response Evaluation Criteria in Solid Tumors (RE-CIST) guidelines, adequate bone marrow, liver, and renal function, and life expectancy of at least 12 weeks. Patients were excluded if they had primary ocular or mucosal melanoma, congestive heart failure, cardiac arrhythmias, active coronary heart disease or ischemia, uncontrolled hypertension, or active CNS metastases. Prior immuno, biologic, or vaccine therapy was allowed, but patients could not have received chemotherapy or prior treatment with inhibitors of the Ras or vascular endothelial growth factor pathways.
Study Design
This randomized, double-blind, placebo-controlled, multicenter, phase II study (clinicaltrials.gov identifier: NCT00110994) was conducted at 17 centers in the United States between April 2005 (first patient first visit) and October 2006 (data cutoff date). Patients were stratified by American Joint Committee on Cancer stage (III unresectable or IV M1a/M1b or IV M1c) and ECOG performance status (0 or 1) and randomly assigned in a 1:1 manner to receive placebo plus dacarbazine or sorafenib plus dacarbazine. Simple stratified randomization with permuted blocks of size 4 was used by the sponsor to create a prospective randomization schedule that was provided to the vendor for the telephone-based interactive voice recognition system (IVRS). Random assignment of eligible patients was performed by designated personnel at each participating site using the IVRS in a double-blind fashion such that the investigator, sponsor, and patient did not know the treatment assignment.
Sorafenib and placebo tablets were supplied by Bayer HealthCare Pharmaceuticals. Dacarbazine was supplied by the study site pharmacy. Patients in both arms received dacarbazine 1,000 mg/m 2 by intravenous infusion on day 1 of a 21-day treatment cycle for up to a maximum of 16 cycles. Sorafenib (400 mg [2 tablets, 200 mg each]) or placebo was administered orally twice a day from day 1 to day 21 continuously. Patients continued to receive therapy during the treatment period until unacceptable toxicity, tumor progression, or death occurred. Toxicity related dose modifications were performed in accordance with protocol-specified guidelines.
This study was conducted in accordance with the Declaration of Helsinki, the Investigational New Drug and Bioresearch Regulations of the Food and Drug Administration, the good clinical practice guidelines, and all applicable local laws and regulations. The study protocol and amendments were approved by local institutional review boards or independent ethics committees. Signed informed consent was obtained from patients before initiation of study treatment.
Study Outcomes
Efficacy. The primary end point of the study was PFS. The secondary and tertiary end points were OS, time to progression (TTP), objective response rate, PFS rates at months 6 and 9, duration of response, and change from baseline in ECOG performance status. In this study, PFS was defined as the time from random assignment until objective tumor progression or death; OS as the time from random assignment until death. TTP was defined as the time from random assignment until objective tumor progression; deaths were censored in the calculation of TTP. Measurements were made at baseline and every 6 weeks thereafter and at the end of the treatment period, if applicable. Disease progression and tumor response were evaluated using modified RECIST guidelines by an independent review committee (IRC). Briefly, all radiographic scans and investigator assessments of cutaneous lesions and lesions assessed by physical examination (with photographic documentation) were collected by investigators and sent to the IRC. The scans were read by at least two blinded radiologists; an independent blinded oncologist integrated the independent blinded radiological assessment with the investigator assessment of the lesions to determine objective response, best overall response, and date of progression. The assessment of best response and progression was also performed by the investigator.
Safety. Safety profile was based on observed adverse events, clinical laboratory tests, results of physical examinations, vital signs assessments (including heart rate, blood pressure, respiration rate, and temperature), ECGs, and weight. Safety assessments were carried out before initiation of treatment, on days 8 and 15 during the first two cycles and, every 3 weeks thereafter, and at the end of treatment, if applicable.
Statistical Analysis
Determination of sample size. Using historical data, a median PFS of 2.5 months was assumed for the placebo plus dacarbazine arm. Based on a logrank test with a two-sided significance level of .05, 77 PFS events would provide 86% power for an alternative hazard ratio (HR) of 0.5 (sorafenib plus dacarbazine/placebo plus dacarbazine). With 77 PFS events, the critical value of the observed HR for statistical significance would be 0.64. A total sample size of 98 patients was sufficient to achieve the target number of PFS events, assuming an exponential distribution for PFS, a 12-month accrual period, and 3.5 additional months of follow-up.
Efficacy analysis. All patients randomly assigned to treatment (intentto-treat [ITT] population) were included in the primary efficacy analyses. For analysis of efficacy outcomes, a two-sided significance level of .05 was used. For the primary end point of PFS, the treatment arms were compared using a log-rank test. Two-sided 95% CIs were calculated for median PFS and the estimated probability of PFS rate at months 6 and 9 based on the Kaplan-Meier estimates. The HR and a two-sided 95% CI for the HR were calculated. Time to progression, duration of response, and OS were analyzed using the same methods as for PFS. These end points were used as supportive evidence for the primary end point. The final analysis of PFS was performed when approximately 77 events (progression or death) were observed; the final analysis of OS was performed when all patients had been observed for at least 15 months. Incidence of best response and change from baseline in performance status at the visit at which best response was first noted, and at the end of treatment (worse, improved, no change) were analyzed using Fisher's exact test. Except when specified, missing data were not estimated or carried forward in any statistical analyses.
Safety analyses. All patients randomly assigned to treatment and receiving any study medication (valid-for-safety population) were included in the safety analyses. In addition to summaries of adverse events classified and graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0, term and category, safety analyses included evaluation of clinically significant laboratory test results and vital signs.
RESULTS
A total of 101 patients with histologically or cytologically confirmed advanced melanoma were randomly assigned between the two treatment arms. The detailed patient disposition is shown in Figure 1 ; the baseline characteristics of patients are presented in Table 1 . All randomly assigned patients were included in the ITT and valid-forsafety populations.
Seven patients had violations of the eligibility criteria (four in placebo plus dacarbazine arm and three in the sorafenib plus dacarbazine arm). The violations were administration of disallowed prior therapy (four patients), previous malignancy other than melanoma within 3 years before study entry (two patients), and no baseline brain magnetic resonance imaging (one patient). All seven patients were allowed to continue on study and were included in the ITT population.
Efficacy
A total of 81 patients experienced disease progression or had died at the time of PFS analysis. The IRC assessed median PFS was 11.7 weeks for the placebo plus dacarbazine arm and 21.1 weeks for the sorafenib plus dacarbazine arm (Table 2 ; Fig 2A) resulting in an estimated HR of 0.665 (sorafenib plus dacarbazine/placebo plus dacarbazine; P ϭ .068). There were no meaningful differences between the treatment arms in the timing of radiological scans compared with the scheduled time. The median time to first scan was 43 days for the placebo plus dacarbazine arm and 42 days for the sorafenib plus dacarbazine arm. The IRC assessment of PFS was comparable to investigator-assessed PFS in both arms. The treatment arms differed significantly in terms of TTP. The median TTP was 11.7 weeks for the placebo plus dacarbazine arm and 21.1 weeks for the sorafenib plus dacarbazine arm (Table 2 , Fig 2B) resulting in an estimated HR of 0.619 (sorafenib plus dacarbazine/placebo plus dacarbazine; P ϭ .039). The treatment arms, placebo plus dacarbazine and sorafenib plus dacarbazine, respectively, also differed significantly in terms of PFS rate at 6 months, 19.5% and 41.0%, and at 9 months, 12.2% and 22.2% (Table 2) . Overall best response and duration of partial response assessed by the IRC are presented in Table 2 . While no statistically significant differences were observed, trends favoring the sorafenib plus dacarbazine arm were seen with both end points. A total of 73 patients had died at the time of the final OS analysis. The median OS was 51.3 weeks for the placebo plus dacarbazine arm and 45.6 weeks for the sorafenib plus dacarbazine arm (Table 2 , Fig 2C) resulting in an estimated HR of 1.022 (sorafenib plus dacarbazine/placebo plus dacarbazine; P ϭ .927). There was no significant difference in change from baseline in ECOG performance status.
Safety
The median duration of placebo and sorafenib treatments were 12.1 and 19.1 weeks, respectively; the median number of cycles of dacarbazine in the placebo plus dacarbazine and sorafenib plus dacarbazine arms were four and five, respectively. Dosing and drug exposure data are presented in Table 3 . While there were more dose reductions in the sorafenib plus dacarbazine arm, patients in this arm generally had a longer exposure to the study drug. Treatmentemergent grade 3/4 adverse events with incidence Ն 5% and the corresponding incidence of adverse events of all grades are presented in Table 4 . One or more grade 3/4 adverse events were reported for 25 patients (50%) in the placebo plus dacarbazine arm and 35 patients (69%) in the sorafenib plus dacarbazine arm. Grade 3/4 hematologic events occurred less frequently in patients treated with placebo plus dacarbazine (32%) than in patients treated with sorafenib plus dacarbazine (51%). The incidence of hematologic events was highest in the first cycle of dosing and progressively decreased during the next three cycles of therapy in both treatment arms. Grade 3 CNS hemorrhages were reported in four patients (8%) in the sorafenib plus dacarbazine arm. In three of these patients, hemorrhage was reported as not related to study medication by the investigators and occurred at a site of disease progression. In two of these three patients, a grade 2 and a grade 4 thrombocytopenia were also observed. In the fourth patient, a subarachnoid hemorrhage was observed and was assessed as possibly related to study medication. In all four patients, no neurological sequelae were observed and all four patients later died due to disease progression. There were no treatment-related deaths observed in either arm.
DISCUSSION
Prior clinical trials investigating dacarbazine and dacarbazinecontaining regimens in the treatment of advanced melanoma have demonstrated minimal to modest antitumor activity. [6] [7] [8] [9] [10] 19, 30 The goal of this randomized, phase II clinical trial was to detect an improvement in efficacy by combining sorafenib with dacarbazine in chemotherapy-naïve patients with advanced melanoma and to further evaluate the safety of this combination of agents. In previous studies with dacarbazine, median PFS times ranging from 1.5 to 1.6 months were observed. 7, 9 In this study, the median PFS in the placebo plus dacarbazine arm was 2.7 months. Analysis of PFS revealed a 50% improvement in PFS for the sorafenib plus dacarbazine arm as compared with the placebo plus dacarbazine arm. This improvement in PFS is particularly encouraging since the observed PFS for placebo plus dacarbazine in this study was nearly twice as long as that observed in other studies. In addition, a statistically significant 62% improvement in TTP and improvements in response rates, duration of response, and PFS rates were observed for patients receiving the sorafenib plus dacarbazine combination as compared with placebo plus dacarbazine.
Randomized phase II clinical trials are often limited by their small sample sizes to detect true treatment differences between the study arms. In this study, we observed improvements in PFS and TTP on the addition of sorafenib to dacarbazine, however, these findings did not translate into an improvement in OS. Consistent with a small sample Abbreviations: HR, hazard ratio; PFS, progression-free survival; OS, overall survival; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease. *HR for sorafenib ϩ dacarbazine/placebo ϩ dacarbazine.
size, the CI for the hazard ratio for OS was wide (.645 to 1.617). Thus, an improvement in OS for patients receiving sorafenib plus dacarbazine in larger clinical trials cannot be excluded based on the results of this study. Another limitation of randomized phase II trials is the increased likelihood of imbalances between the treatment arms because the study design does not usually allow for extensive stratification of even the most common prognostic factors. In this study, patients were stratified by American Joint Committee on Cancer stage and ECOG performance status. At baseline, the two treatment arms were well balanced except for lactate dehydrogenase (LDH) levels and time since diagnosis of metastatic disease. There were more patients with high LDH levels in the placebo plus dacarbazine arm; however, this finding may be the result of a greater incidence of missing LDH data in the sorafenib plus dacarbazine arm. The median time since diagnosis of metastatic disease was longer for patients in the placebo plus dacarbazine arm (6.8 v 4.1 months). This difference may be partially attributed to a greater percentage of patients in the placebo plus dacarbazine arm having received prior systemic therapy (immuno, biologic, or vaccine therapy). It is possible that these imbalances between the two treatment arms may have biased the outcome of this trial.
Recently, results of a randomized phase III study of sorafenib in combination with carboplatin and paclitaxel in patients (N ϭ 270) with advanced melanoma who had progressed on a dacarbazine-or temozolomide-containing regimen were presented. 31 Unfortunately, no improvements in PFS and OS were observed with the addition of sorafenib to the carboplatin-paclitaxel regimen in this patient population. A phase III cooperative group trial (E2603) is currently investigating the sorafenib, carboplatin, and paclitaxel combination in A chemotherapy-naïve patients with advanced melanoma. It remains to be seen if the encouraging efficacy results observed on adding sorafenib to dacarbazine in chemotherapy-naïve patients in this trial will hold true when sorafenib is added to the carboplatin and paclitaxel regimen in a similar treatment setting. In regard to tolerability and safety, patients in the sorafenib plus dacarbazine arm were on the study for a longer period of time (median, 19 v 12 weeks); as expected, dose reductions occurred more frequently for patients receiving sorafenib. A similar trend was observed in exposure to and dose reductions of dacarbazine. While the incidence of adverse events, especially thrombocytopenia and neutropenia, was greater in the sorafenib plus dacarbazine arm, the combination was well tolerated with a manageable toxicity profile. Although in this study, CNS hemorrhage was reported in four patients in the sorafenib plus dacarbazine arm, it has not been observed in other advanced melanoma trials employing sorafenib plus dacarbazine or temozolomide. [27] [28] [29] 32 Further, in the aforementioned phase III study of paclitaxel and carboplatin with or without sorafenib in patients with advanced melanoma, CNS hemorrhage was observed for two of 134 sorafenib plus carboplatin plus paclitaxel patients and one of 134 placebo plus carboplatin plus paclitaxel patients.
31
Based on the results of this study, the combination of sorafenib and dacarbazine in chemotherapy-naïve patients with advanced melanoma yielded encouraging efficacy results and was well tolerated with a manageable toxicity profile. The findings observed in this study are consistent with those obtained in a single-arm phase II trial utilizing the same combination of agents.
28 Given these encouraging results, randomized phase III trials of sorafenib and dacarbazine in the treatment of advanced melanoma are warranted to unequivocally establish the benefit of this treatment combination.
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